Furthermore, Chen Wongworawat et al. recently identified distinct FCGR3A-high monocyte/macrophage subpopulations involved in kidney transplant rejection, reinforcing the emphasis on macrophage-driven pathology and supporting the broader idea that targeting specific innate immune pathways, such as ILK, may offer therapeutic benefits in CKD-related vascular complications [50]. This evidence concerns the gene FCGR3A and chronic kidney disease.